Jul. 10, 2020
The changes in this bulletin apply to all groups that use the Net Cost Formulary. These changes include decisions that occurred as a result of our June 2020 Pharmacy and Therapeutics Committee (P&T) meeting.
Jun. 22, 2020
On May 28, 2020, the FDA announced that laboratory testing has revealed levels of N-nitrosodimethylamine (NDMA) above the agency’s acceptable intake limit in several lots of the extended-release (ER) formulation of metformin.
May. 18, 2020
The changes in this bulletin apply to all groups that use the Net Cost Formulary.
Apr. 27, 2020
Effective immediately, the preferred specialty pharmacy for PAI will be known as Optum Specialty Pharmacy, formerly BriovaRx.
Apr. 02, 2020
PAI and OptumRx have developed a new Quantity Limit policy to provide clinical guidance for prescribing hydroxychloroquine/chloroquine related to COVID-19 treatment.
Apr. 02, 2020
The FDA announced that it is requesting manufacturers withdraw all prescription and over-the-counter (OTC) ranitidine drugs from the market immediately due to contamination with N-Nitrosodimethylamine (NDMA).
Mar. 05, 2020
As a part of our PBM’s strategy for battling the national opioid epidemic, effective March 1, 2020, home delivery through OptumRx will require e-prescriptions for ALL controlled substances [for example, opioids for pain, stimulant drugs used to treat Attention Deficit Disorder (ADD) and Attention Deficit Hyperactivity Disorder (ADHD)].
Feb. 28, 2020
The FDA announced the request to voluntarily withdraw Belviq, Belviq XR (lorcaserin) from the U.S. market because a safety clinical trial showed an increased occurrence of cancer.
Sep. 04, 2019
We are taking steps to ensure our members’ health care coverage needs are continuous and flexible in the event of a storm.
Jul. 08, 2019
PAI is making some adjustments to our prescription drug lists and pharmacy programs as part of our continued effort to cover medications that are appropriate, as well as cost-effective, for members.